Novo Nordisk acquires Manufacturing Campus from Novavax

Andersen Corporate Finance is proud to announce its role in advising Novavax, a global leader in vaccine development, on the $200 million sale of its advanced manufacturing campus inthe Czech Republic to Novo Nordisk, a world-renowned healthcare company.

‍

The transaction includes a 150,000-square-foot, state-of-the-art recombinant protein manufacturing facility equipped with support buildings, essential infrastructure, and a highly skilled workforce. This strategically significant deal enables Novo Nordisk to expand its production capabilities while allowing Novavax to focus on its core mission of advancing vaccine development for serious infectious diseases.

Joachim Schulz, Managing Partner of Andersen in the Netherlands, led the advisory team, guiding Novavax through the process and securing Novo Nordisk as the ideal partner for this strategic sale.

‍

This deal highlights Andersen’s expertise in complexcross-border biotech transactions and its commitment to delivering strategic solutions for global clients.

‍